about
Glucose deprivation induces G2/M transition-arrest and cell death in N-GlcNAc2-modified protein-producing renal carcinoma cells.Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic reviewInterleukin-22 suppresses the growth of A498 renal cell carcinoma cells via regulation of STAT1 pathway.Forkhead box J1 expression is upregulated and correlated with prognosis in patients with clear cell renal cell carcinoma.Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal cell carcinoma is a primary target for therapy by tyrosine kinase inhibitors.let-7b and let-7c are determinants of intrinsic chemoresistance in renal cell carcinoma.5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma.Gene expression profiling of the synergy of 5-aza-2'-deoxycytidine and paclitaxel against renal cell carcinoma.TPX2 in human clear cell renal carcinoma: Expression, function and prognostic significance.Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.VHL promotes immune response against renal cell carcinoma via NF-κB-dependent regulation of VCAM-1.Interferon-α enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activityThe metastasis suppressor CD82/KAI1 regulates cell migration and invasion via inhibiting TGF-β 1/Smad signaling in renal cell carcinoma.Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis.Combination of mTOR and MAPK Inhibitors-A Potential Way to Treat Renal Cell Carcinoma.
P2860
Q30438694-8AE6F317-928D-4838-A1CC-901B95D9A15AQ33591376-C8409D9C-CD23-475D-A848-846ED588FF75Q33916153-F9ECBEB0-FDC1-4DC1-AEF3-80601149B46EQ34503610-D449EF5D-818C-4CFD-8940-E07262429F57Q35082185-3E6DCE20-1FBA-47A4-AFB2-1CA8E9527968Q35590660-53DD7598-AFFF-4B24-ACAC-F361D1B735CCQ36084341-190A944F-FECD-456C-8A87-920C586DDFE8Q36348109-1288492C-3297-4D82-8D10-AC6E7C0EEACBQ36825650-9F4744EA-52DC-4398-8725-52AFEF8D5BD5Q37481890-067A1D45-5D46-4032-A7A7-30554A38E9D6Q38714947-8E0129EA-5A07-45A3-B6C5-7D526084D7A1Q40817688-5A6E8CE3-D592-4453-96E7-D7E8B0D3028CQ41612890-0484875B-EEA2-42F1-8E7E-4844040219EBQ41921665-6F1D6288-655E-457B-A2A5-F5803A601D79Q42705608-2873D54A-F915-422B-8DFE-81269A2E3865
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Chemotherapy for renal cell carcinoma.
@ast
Chemotherapy for renal cell carcinoma.
@en
type
label
Chemotherapy for renal cell carcinoma.
@ast
Chemotherapy for renal cell carcinoma.
@en
prefLabel
Chemotherapy for renal cell carcinoma.
@ast
Chemotherapy for renal cell carcinoma.
@en
P1433
P1476
Chemotherapy for renal cell carcinoma.
@en
P2093
Bokemeyer C
Hartmann JT
P304
P407
P577
1999-03-01T00:00:00Z